RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
181 hedge funds and large institutions have $2.69B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 71 increasing their positions, 55 reducing their positions, and 31 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
181
Holders Change
-13
Holders Change %
-6.7%
% of All Funds
3.18%
Holding in Top 10
2
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-71.43%
% of All Funds
0.04%
New
19
Increased
71
Reduced
55
Closed
31
Calls
$39.3M
Puts
$94.7M
Net Calls
-$55.3M
Net Calls Change
-$31M
Top Buyers
| 1 |
Invesco
Atlanta,
Georgia
|
$346M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
$68.9M |
| 3 |
Goldman Sachs
New York
|
$17.8M |
| 4 |
Morgan Stanley
New York
|
$16.5M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
$15.8M |
